SCHEMBL1745366

SCHEMBL1745366

COC(=O)CCc1ccc(OCc2ccc(C(=O)c3ccc(Cl)cc3)cc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.60
MAOA P21397 1/20 0.60
RAB9A P51151 3/20 0.58
NPC1 O15118 2/20 0.58
NR4A2 P43354 1/20 0.58
FFAR1 O14842 1/20 0.52
ALDH1A1 P00352 4/20 0.51
HTT P42858 3/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
KMT2A Q03164 1/20 0.50
ATM Q13315 1/20 0.50
HPGD P15428 1/20 0.50
VNN1 O95497 1/20 0.49
PKM P14618 1/20 0.49
MAPT P10636 3/20 0.49
GAA P10253 1/20 0.49
SRD5A2 P31213 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1747202 0.88 SMN1; SMN2 (0.67) MAOBRAB9ANPC1NR4A2FFAR1
SCHEMBL1746654 0.85 FFAR1 (0.67) MAOBMAOANR4A2FFAR1ALDH1A1
SCHEMBL1745397 0.82 FFAR1 (0.58) RAB9ANPC1FFAR1ALDH1A1HTT
SCHEMBL21992633 0.82 MAOB (0.60) MAOBMAOARAB9ANPC1NR4A2
SCHEMBL197699 0.82 CYP11B1 (0.58) FFAR1ALDH1A1HTTL3MBTL1KMT2A
SCHEMBL1747136 0.81 FFAR1 (0.72) MAOBRAB9ANPC1FFAR1SMN1; SMN2
SCHEMBL21991800 0.81 HPGD (0.58) MAOBMAOARAB9ANPC1ALDH1A1
SCHEMBL15679198 0.81 FFAR1 (0.60) MAOBFFAR1ALDH1A1L3MBTL1KMT2A
SCHEMBL1745247 0.81 FFAR1 (0.72) MAOBRAB9ANPC1FFAR1SMN1; SMN2
SCHEMBL3468096 0.81 F2RL1 (0.63) RAB9ANPC1ALDH1A1SMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR MAOB 4303/4885MAOA 4245/4885RAB9A 2029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.